首页> 外文期刊>Journal of Clinical Microbiology >Development of a Novel PCR Restriction Analysis of the hsp65 Gene as a Rapid Method To Screen for the Mycobacterium tuberculosis Complex and Nontuberculous Mycobacteria in High-Burden Countries
【24h】

Development of a Novel PCR Restriction Analysis of the hsp65 Gene as a Rapid Method To Screen for the Mycobacterium tuberculosis Complex and Nontuberculous Mycobacteria in High-Burden Countries

机译:hsp65基因的新型PCR限制性分析的发展,作为在高负担国家筛查结核分枝杆菌复合体和非结核分枝杆菌的快速方法

获取原文
获取外文期刊封面目录资料

摘要

The limitations of conventional methods of identification of Mycobacterium tuberculosis have led to the development of several nucleic acid amplification techniques which have the advantage of being rapid, sensitive, and specific. However, their expense or the need for technical expertise makes it difficult to use them in regions in which tuberculosis is endemic. A novel PCR restriction analysis (PRA) of the hsp65 gene was therefore developed for rapid screening of clinical isolates to identify Mycobacterium spp. The restriction enzymes NruI and BamHI were selected to obtain a limited number of restriction patterns to further differentiate between Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacteria (NTM). Three hundred ten isolates from clinical specimens and 24 reference strains were tested. The assay correctly identified 295 of the 310 culture isolates as MTBC, while the remaining 15 isolates were identified as NTM. Of the isolates tested, 135 MTBC strains and all 15 NTM were also confirmed by PRA using Sau96I and CfoI. Thirty-eight randomly selected MTBC strains and all 15 NTM were further confirmed by sequencing. The NruI/BamHI PRA was simple, as it did not require any elaborate analyses. It was cost-effective, rapid, highly sensitive, and specific and did not require technical expertise. The assay can, therefore, be used as a simple screening test not only to detect Mycobacterium spp. but also to differentiate MTBC from NTM in peripheral laboratories with minimal availability of funds.
机译:传统的鉴定结核分枝杆菌的方法的局限性导致了几种核酸扩增技术的发展,这些技术具有快速,灵敏和特异的优势。然而,它们的费用或对技术专长的需求使得难以在结核病流行的地区使用它们。因此,开发了一种新型的 hsp65 基因的PCR限制性酶切分析(PRA),以快速筛选临床分离株以鉴定分枝杆菌属。选择限制酶NruI和BamHI以获得有限数量的限制模式,以进一步区分结核分枝杆菌复合体(MTBC)和非结核分枝杆菌(NTM)。测试了来自临床标本和24个参考菌株的310个分离株。该测定法正确地将310个培养物中的295个分离物鉴定为MTBC,而其余15个分离物被鉴定为NTM。使用Sau96I和CfoI,PRA还确认了135个MTBC菌株和所有15个NTM。通过测序进一步确认了38个随机选择的MTBC菌株和所有15个NTM。 NruI / BamHI PRA很简单,因为它不需要任何详尽的分析。它具有成本效益,快速,高度敏感和特定性,并且不需要技术专家。因此,该测定法不仅可以用于检测分枝杆菌属,还可以用作简单的筛选试验。而且还可以在资金最少的情况下使MTBC与NTM在外围实验室中脱颖而出。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号